



For patients receiving IG therapy

SUPPORT THAT KEEPS HEALTH IN FOCUS

Financial assistance, education, and
personalized guidance to help support
patients from the start and along the way



IG, immune globulin.

GRIFOLS

Please see Important Safety Information on pages 7-11, and refer to the accompanying Prescribing Information for **GAMUNEX-C** and **XEMBIFY**.

GET TO KNOW CONNEXIONS



Managing IG treatment can come with questions and uncertainty. Connexions is here to help patients and healthcare teams with support every step of the way.

What is Connexions?

Connexions is a personalized support program for patients receiving GAMUNEX-C or XEMBIFY. Connexions works with patients and healthcare providers to determine which services can best support them.

Connexions can help reduce financial barriers, simplify the insurance process, provide access to educational materials, and help patients focus on their health.

Getting started is simple

Connexions offers several ways for patients to enroll:

- **Call us** Monday through Friday, 8 AM to 8 PM ET



1-888-MYGAMUNEX
(1-888-694-2686)



1-844-MYXEMBIFY
(1-844-699-3624)

- **Enroll online**

Healthcare providers can help patients get set up or patients can enroll themselves.



Scan to get started or visit: www.connexions.grifols.com

- **Complete the enrollment form**

Fill out forms using the links below and then send them via email or fax.

[\[GAMUNEX Connexions Form\]](#)

[\[XEMBIFY Connexions Form\]](#)

Email: grifolsconnexions@cardinalhealth.com

Fax: 1-877-375-0758

IG, immune globulin.

Please see Important Safety Information on pages 7-11, and refer to the accompanying Prescribing Information for [GAMUNEX-C](#) and [XEMBIFY](#).



COPAY ASSISTANCE TO HELP MANAGE TREATMENT COSTS



Patients with commercial insurance may qualify for copay assistance through Connexions



Eligible patients can receive up to \$10,000 of copay assistance per calendar year*

- Copay assistance can be used to help cover copays, coinsurance, and deductibles.
- Patients must have commercial insurance that:
 - Covers medication costs
 - Allows for copay or coupon assistance
- No per-infusion limit
- No income requirement or paperwork
- Patient may not be enrolled in government-funded healthcare programs, such as Medicare, Medigap, Medicaid, VA, DOD, or Tricare



Connexions can answer questions from patients and providers about copay assistance

- Providers register eligible patients and submit claims.
- Patients can create an account to view their copay information.



“It was very positive for us to learn that GAMUNEX-C has a patient support program.”

— BUD, a real patient with CIDP

CIDP, chronic inflammatory demyelinating polyneuropathy.

*Review terms and conditions at www.GAMUNEX-C.com or www.XEMBIFY.com.

Please see Important Safety Information on pages 7-11, and refer to the accompanying Prescribing Information for [GAMUNEX-C](#) and [XEMBIFY](#).



SUPPORT FOR PATIENTS WITHOUT INSURANCE



Patients may be eligible to receive medication at no cost through the Patient Support Program (PAP)



Requirements to qualify for the PAP

- Total household income is less than or equal to 400% of the federal poverty level
- Patient is uninsured or has an insurance plan that does not cover specialty pharmaceuticals
- Prescribed for the following diagnoses: GAMUNEX-C for PI or CIDP; XEMBIFY for PI
- Patient is a resident of the United States, excluding territories
- Patient may not be enrolled in government-funded healthcare programs, such as Medicare, Medigap, Medicaid, VA, DOD, or Tricare

Patients who may qualify for the PAP can call Connexions today

Applying for the PAP

- To apply, the patient and provider complete the PAP application form, the provider completes a prescription referral form, and the patient enrolls in Connexions.
- Call Connexions to learn more about PAP.



“Don’t hesitate to seek information. Don’t hesitate to seek help.”

— JAMES, a real patient with CIDP

CIDP, chronic inflammatory demyelinating
polyneuropathy; PI, primary immunodeficiency disease.

**Please see Important Safety Information
on pages 7-11, and refer to the
accompanying Prescribing Information
for [GAMUNEX-C](#) and [XEMBIFY](#).**



PERSONALIZED SUPPORT EVERY STEP OF THE WAY



Every IG treatment journey is different. The support services and educational resources from Connexions are designed to help patients and healthcare teams confidently navigate treatment.

PATIENTS

- ✓ Dedicated case managers
- ✓ Financial assistance programs
- ✓ Insurance benefits verification
- ✓ Educational resources about disease and treatment
- ✓ Contact with patient organizations for additional support and resources

HEALTHCARE TEAM

- ✓ Dedicated case managers
- ✓ Benefits investigation upon request
- ✓ Support for prior authorizations and appeals
- ✓ Consultation with a Grifols IG Nurse Educator for healthcare providers
- ✓ Resources including coding and billing guides and sample letters

Connexions provides additional resources to accompany your treatment journey and enhance your understanding

- Opt in for Patient Education to receive product updates, tips and tools for managing therapy, and information about upcoming events.
- For patients receiving XEMBIFY, request a Patient Starter Kit with resources to help prepare for treatment, develop a good routine, and keep track of infusions.



“Do not be afraid to advocate for yourself from the beginning.”

— STEPHANIE, a real patient with CIDP

CIDP, chronic inflammatory demyelinating polyneuropathy; IG, immune globulin.

Please see Important Safety Information on pages 7-11, and refer to the accompanying Prescribing Information for [GAMUNEX-C](#) and [XEMBIFY](#).



STAY INFORMED, CONNECTED, AND PREPARED



Empower yourself through knowledge

Explore these websites for disease education, product information, what to expect with treatment, resources for tracking infusions, and more.



www.GAMUNEX-C.com



www.XEMBIFY.com

Find extra support from these trusted organizations

These organizations offer extensive educational resources, as well as virtual and in-person events, to help people living with PI and CIDP connect with each other.



www.primaryimmune.org



www.gbs-cidp.org



“We went online where we got financial information and a lot of good information about treatment, how it worked, and what infusions would look like.”

— VICKIE, a real caregiver for a patient with CIDP

CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barré syndrome; PI, primary immunodeficiency disease.

Please see Important Safety Information on pages 7-11, and refer to the accompanying Prescribing Information for [GAMUNEX-C](#) and [XEMBIFY](#).



IMPORTANT SAFETY INFORMATION

GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) is approved to treat primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. If you have PIDD, you may take GAMUNEX-C under the skin (subcutaneously) or in a vein (intravenously). GAMUNEX-C is also approved to treat idiopathic thrombocytopenic purpura (ITP) in adults and children and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. If you have ITP or CIDP, you may only take GAMUNEX-C intravenously.

If you take GAMUNEX-C or a similar immune globulin product, you could experience a serious and life-threatening blood clot (thromboembolism), which may include pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness, or weakness on one side of the body. You are more likely to develop a blood clot if you have a history of hardening of the arteries (atherosclerosis), stroke, heart attack, or heart failure (low volume of blood pumped by the heart). You may also be more likely to get a blood clot if you are elderly, if you have a blood clotting disorder, if you are inactive for long periods of time (such as long bed rest), if you use estrogens, or if you have thickening of your blood. For patients at risk, GAMUNEX-C should be administered at the lowest dose and slowest infusion rate that is practical. However, blood clots may occur in the absence of any of the known risk factors. Patients should be well hydrated by drinking enough water before GAMUNEX-C is administered. Tell your doctor immediately if your medical history is similar to what is described here, and especially if you start having any of these symptoms while taking GAMUNEX-C.

If you take GAMUNEX-C or a similar immune globulin product intravenously, you could experience serious kidney disease and death. You may have symptoms of decreased urination, sudden weight gain, swelling in your legs (edema), or shortness of breath. You are more likely to develop serious kidney disease if you already have a kidney problem, have Type II diabetes mellitus, or are older than 65. You are more likely to develop serious kidney disease if you are dehydrated, have a blood infection (sepsis), have high protein content in your blood, or if you are receiving other medicines that are harmful to your kidneys. Tell your doctor immediately if your medical history is similar to what is described here, and especially if you start having any of these symptoms while taking GAMUNEX-C.

You are more likely to develop serious kidney disease if you take an intravenous immune globulin product that contains sugar (sucrose). GAMUNEX-C does not contain sugar. If your situation makes you more likely to experience serious kidney disease, you should take GAMUNEX-C at the lowest concentration available and the slowest infusion rate that is practical.

Please see accompanying [Prescribing Information](#) for GAMUNEX-C.



IMPORTANT SAFETY INFORMATION (cont.)

Do not take GAMUNEX-C if you have an allergy to immune globulin. Tell your doctor if you have had a serious reaction to other medicines that contain human immune globulin. Also tell your doctor if you have immunoglobulin A (IgA) deficiency. If you have a serious reaction while taking GAMUNEX-C, stop taking it immediately and tell your doctor.

Periodic monitoring of kidney function and urine output is particularly important in patients more likely to experience severe kidney disease.

You could experience other serious and life-threatening problems due to immune globulin. You could get aseptic meningitis (a type of brain inflammation with symptoms of severe headache, stiff neck, fatigue, fever, sensitivity to light, painful eye movements, nausea, and vomiting), a blood problem called hemolytic anemia (common symptoms include increased heart rate, fatigue, yellow skin or eyes, and dark-colored urine), and/or a lung problem called transfusion-related acute lung injury (commonly referred to as TRALI). TRALI is a condition where you build up fluid in the lungs (called pulmonary edema) that is not the result of heart failure.

If you have higher than normal body fluid volumes or if you have a condition where increasing body fluid volume may be a concern, a higher dose, such as 1g/kg for 1-2 days, is not recommended.

Because GAMUNEX-C is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

You may not take GAMUNEX-C subcutaneously if you have ITP. **If you have ITP and take GAMUNEX-C subcutaneously, you could experience a very serious and life-threatening black and blue wound (hematoma, which is a pocket of blood within a tissue).**

After you take GAMUNEX-C, your blood antibody levels may rise, which could cause some blood antibody tests to give false results.

The most common side effects in a clinical study with PIDD patients who got subcutaneous injections of GAMUNEX-C were infusion-site reactions such as redness, swelling, and itching; extreme tiredness; pain in the region of the head or neck; a runny nose, nasal congestion, sneezing, cough, and sputum production; joint pain; loose stools; a sensation of unease and discomfort in the upper stomach; swelling of the tissue lining the sinuses; inflammation of the airways that carry air to your lungs; a feeling of unhappiness, sadness, melancholy, gloom, hopelessness, or low spirits; red rash or bumps, itchy, swollen, and tender skin with or without blisters or a burning feeling; a severe throbbing pain or a pulsing sensation, usually on just one side of the head; muscle pain; familiar infectious diseases such as the common cold or flu; and raised body temperature or fever. In clinical studies with PIDD patients who got GAMUNEX-C intravenously, the most common side effects were cough; irritation and inflammation of the mucous membrane inside the nose; sore throat caused by inflammation of the back of the throat; pain in the region of the head or neck; a condition in which your airways narrow and swell and produce extra mucus; a sensation of unease and discomfort in the upper stomach; raised body temperature or fever; loose stools; and swelling

Please see accompanying [Prescribing Information](#) for GAMUNEX-C.



IMPORTANT SAFETY INFORMATION (cont.)

of the tissue lining the sinuses. In a clinical study with CIDP patients who got GAMUNEX-C intravenously, the most common side effects were pain in the region of the head or neck; raised body temperature or fever; abnormally high blood pressure; feelings of coldness accompanied by shivering; a noticeable change in the texture or color of your skin such as your skin becoming scaly, bumpy, itchy, or otherwise irritated; a sensation of unease and discomfort in the upper stomach; joint pain; and abnormal physical weakness or lack of energy. In clinical trials with ITP patients who got GAMUNEX-C intravenously, the most common side effects were pain in the region of the head or neck; a discoloration of the skin resulting from bleeding underneath, typically caused by bruising; vomiting, fever, nausea, rash, abdominal pain, back pain, and a pain or an uncomfortable feeling in the upper middle part of your stomach.

The most serious side effects in clinical studies were a blood clot to the lung (pulmonary embolism) in 1 patient with a history of this condition (in CIDP), a flare-up of an existing type of anemia (autoimmune pure red cell aplasia) in 1 patient (in PIDD), and heart inflammation (myocarditis) in 1 patient (in ITP).

Please see accompanying [Prescribing Information](#) for GAMUNEX-C.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



IMPORTANT SAFETY INFORMATION

What is XEMBIFY®?

XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin used in the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

- **Thrombosis (formation of blood clots within blood vessels) may occur with immune globulin products, including XEMBIFY. Before you take XEMBIFY, talk to your doctor if you:**
 - Are older
 - Are sedentary (need to lie down or sit down) for long periods of time
 - Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
 - Have a permanent intravenous (IV) catheter
 - Have hyperviscosity of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
 - Have cardiovascular (heart) problems or previous history of stroke
- Thrombosis may occur even if you don't have any risk factors
- If you are at risk of thrombosis, your doctor may prescribe XEMBIFY at the minimum dose and infusion rate. Make sure you drink plenty of fluid before taking XEMBIFY. Make sure your doctor is checking you regularly for signs and symptoms of thrombosis and is checking your blood viscosity if you are at risk of hyperviscosity

Who should not use XEMBIFY?

- XEMBIFY should not be used if you have had a severe allergic reaction to human immune globulin, or if you have been told by a doctor that you are IgA deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product

What are possible serious side effects of XEMBIFY?

- **Aseptic meningitis syndrome (AMS).** Aseptic meningitis is a non-infectious inflammation of the membranes that cover the brain. It causes a severe headache syndrome, which may occur with human immune globulin treatment, including XEMBIFY. If you are showing signs and symptoms of AMS, your doctor may conduct a thorough neurological evaluation including spinal tap (sampling fluid which surrounds the spinal cord) to rule out other causes of meningitis. Stopping human immune globulin treatment has resulted in the end of signs and symptoms within several days. Treatment may include analgesics (pain medicines) and/or a special procedure known as a “blood patch” to stop headache
- **Hypersensitivity.** Severe allergic reactions may occur with immune globulin products, including XEMBIFY. If you have a severe allergic reaction, stop the infusion immediately and get medical attention. XEMBIFY contains IgA. If you have known antibodies to IgA, you may have a greater risk of developing potentially severe allergic reactions

**Please see accompanying full
[Prescribing Information](#) for XEMBIFY.**



IMPORTANT SAFETY INFORMATION (cont.)

- **Kidney problems or failure.** Kidney problems or failure may occur with use of human immune globulin products, especially those containing sucrose (sugar). XEMBIFY does not contain sucrose. If you have kidney disease or diabetes with kidney involvement, your doctor should perform a blood test to assess your hydration level and kidney function before beginning immune globulin treatment and at appropriate intervals thereafter. If your doctor determines that kidney function is worsening, they may discontinue treatment
- **Hemolysis.** Your doctor should monitor you for symptoms of hemolysis (destruction of red blood cells causing anemia, or low red blood cell count). If your doctor suspects hemolysis, they should perform additional tests to confirm
- **Transfusion-related acute lung injury (TRALI).** TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress following transfusion. If your doctor suspects TRALI, they will monitor you for any other lung issues. TRALI may be managed with oxygen therapy
- **Transmissible infectious agents.** Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of XEMBIFY
- **Interference with lab tests.** Because XEMBIFY contains a variety of antibodies, blood tests to determine antibody levels may be falsely elevated. Be sure to tell your doctor or lab technician that you are using XEMBIFY

What are other possible side effects of XEMBIFY?

- In clinical studies of XEMBIFY, some patients experienced local side effects (at the injection site) including pain, redness, puffiness, bruising, nodules, itching, firmness, scabbing and swelling at the site on the skin where the injection occurred. Some patients experienced non-injection-site side effects including cough and diarrhea
- Use of XEMBIFY may interfere with the immune response to virus vaccines, such as vaccines for measles, mumps, rubella and varicella. Tell your doctor you are taking XEMBIFY before getting vaccinations

Please see accompanying [Prescribing Information](#) for XEMBIFY.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



SUPPORT DESIGNED WITH YOU IN MIND

Personalized support, helpful resources, and
customized guidance from the start

READY TO GET STARTED?

CALL CONNEXIONS TODAY

MONDAY TO FRIDAY, 8 AM TO 8 PM ET



1-888-MYGAMUNEX
(1-888-694-2686)



1-844-MYXEMBIFY
1-844-699-3624

OR



SCAN TO ENROLL ONLINE OR VISIT:
WWW.CONNEXIONS.GRIFOLS.COM

Please see Important Safety Information on pages 7-11, and refer to the accompanying Prescribing Information for GAMUNEX-C and XEMBIFY.

GRIFOLS

© 2026 Grifols All rights reserved June 2026 US-GXC-2600105